EUS-FNA and biomarkers for the staging of non-small cell lung cancer

Endoscopy

Volumn 38, Issue SUPPL. 1, 2006, Pages

  Al Haddad, M ^a   Wallace, Michael B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GLYCOSAMINOGLYCAN; K RAS PROTEIN; ONCOPROTEIN; PROTEIN LUNX; PROTEIN P53; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; ASIAN; BONE MARROW METASTASIS; BREAST CANCER; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; EPITHELIUM CELL; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MARKER GENE; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; NEEDLE BIOPSY; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SAFETY; SEX DIFFERENCE; SMOKING; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; ENDOSONOGRAPHY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MEDIASTINUM; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33745993550     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946470     Document Type: Article

References (64)

1. Ries LAG, E M, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK. SEER Cancer Statistics Review. 2002
2. Landis SH et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49 (1): 8-31
3. Wallace MB et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann Thorac Surg 2001; 72 (6): 1861-1867
4. Gupta NC et al. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001; 120 (2): 521-527
5. Dwamena BA et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213 (2): 530-536
6. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111 (6): 1718-1723
7. Dobashi K et al. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 1997; 114 (3): 339-346
8. Dowlatshahi K et al. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80 (7): 1188-1197
9. Izbicki JR et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337 (17): 1188-1194
10. Miller JD, Gorenstein LA, Patterson GA. Staging: the key to rational management of lung cancer. Ann Thorac Surg 1992; 53 (1): 170-178
11. Gress FG et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med 1997; 127 (8 Pt 1): 604-612
12. Wiersema MJ et al. Preoperative staging of non-small cell lung cancer: transesophageal US-guided fine-needle aspiration biopsy of mediastinal lymph nodes. Radiology 1994; 190 (1): 239-342
13. Fritscher-Ravens A et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003; 123 (2): 442-451
14. Harewood GC et al. Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. Mayo Clin Proc 2002; 77 (2): 155-164
15. Gress FG et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study [see comments]. Ann Intern Med 1997; 127 (8 Pt 2): 604-612
16. Silvestri GA et al. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg 1996; 61 (5): 1441-5; discussion 1445-1446
17. Wiersema MJ et al. Preoperative staging of non-small cell lung cancer: transesophageal US-guided fine-needle aspiration biopsy of mediastinal lymph nodes. Radiology 1994; 190 (1): 239-242
18. Salerno CT et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest 1998; 113 (6): 1526-1532
19. Maruyama R et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997; 114 (4): 535-543
20. Chen ZL et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85 (6): 493-498
21. Wallace MB et al. Detection of telomerase expression in mediastinal lymph nodes of patients with lung cancer. Am J Respir Crit Care Med 2003; 167 (12): 1670-1675
22. Wallace MB et al. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest 2005; 127 (2): 430-437
23. Mori M et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55 (15): 3417-3420
24. Noguchi S et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996; 148 (2): 649-656
25. Lockett MA et al. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients. Am Surg 1998; 64 (6): 539-43; discussion 543-454
26. Mitas M et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001; 93 (2): 162-171
27. Hashimoto T et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res 2000; 60 (22): 6472-6478
28. Pallisgaard N et al. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999; 26 (4): 355-365
29. Mensink E et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102 (3): 768-774
30. Emig M et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13 (11): 1825-1832
31. Cassinat B et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14 (2): 324-328
32. Bostick PJ et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16 (8): 2632-2640
33. Iwao K et al. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001; 91 (4): 433-437
34. Perez MS, Walker LE. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Immunol 1989; 142 (10): 3662-3667
35. Latza U et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990; 43 (3): 213-219
36. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40 (1): 17-24
37. Kim NW et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266 (5193): 2011-2015
38. Kolquist KA et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19 (2): 182-186
39. Saretzki G et al. hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 2002; 176 (1): 81-91
40. Marchetti A et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 2002; 82 (6): 729-736
41. Toomey D et al. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 2001; 92 (10): 2648-2657
42. Hara H et al. Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer. Lung Cancer 2001; 34 (2): 219-226
43. Komiya T et al. Prognostic significance of hTERT expression in non-small cell lung cancer. Int J Oncol 2000; 16 (6): 1173-1177
44. Taga S et al. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 1999; 230 (5): 715-720
45. Kim JK et al. Activation of telomerase by silica in rat lung. Toxicol Lett 2000; 111 (3): 263-270
46. Nozaki Y et al. Induction of telomerase activity in fibroblasts from bleomycin-injured lungs. Am J Respir Cell Mol Biol 2000; 23 (4): 460-465
47. Kumaki F et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001; 32 (2): 188-195
48. Xinarianos G et al. Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease. Lung Cancer 2000; 28 (1): 37-42
49. Sumida T et al. Clinical usefulness of telomerase assay for the detection of lymph node metastasis in patients with oral malignancy. Arch Pathol Lab Med 2000; 124 (3): 398-400
50. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-15
51. Brabender J et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001; 7 (7): 1850-1855
52. Selvaggi G et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15 (1): 28-32
53. Swinson DE, Cox G, O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer 2004; 91 (7): 1301-1307
54. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4 (7): 397-406
55. Kris MG et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003; 290 (16): 2149-2158
56. Perez-Soler R et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22 (16): 3238-3247
57. Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21): 2129-2139
58. Paez JG et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676): 1497-1500
59. Cappuzzo F et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97 (9): 643-655
60. Marchetti A et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23 (4): 857-865
61. Shigematsu H et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97 (5): 339-346
62. Yang SH et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005; 11 (6): 2106-2110
63. Kim KS et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005; 11 (6): 2244-2251
64. Tsao MS et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353 (2): 133-144